About this trial
Iron is an essential micronutrient responsible for a whealth of biological processes of the human body. Iron plays a fundamental role especially in oxygen transport, by binding to hemoglobin in the blood circulation. Iron intake from the diet needs to be in balance the unavoidable losses that occur daily via different pathways. The recommended daily requirement of iron is based on the balance between absorption and losses and is calculated to maintain a balance so that the absorption equals losses. At higher altitudes, the absorption of iron may be higher due to adaptation mechanisms in response to low oxygen concentration, and to maintain a larger erytroid compartement. However, the long-term effects of altitude on iron balance are unknown. Filling this knowledge gap is important to better understand iron deficiency in populations living at high and moderate altitudes. Therefore, the investigators plan to study people that live at two different altitudes and measure iron absorption and losses over the long term. This will be useful to formulate specific recommendations for this population groups, to expand the knowledge base to better prevent iron deficiency in Switzerland but also worldwide. Participants will be asked to consume a dose of stable iron isotopes. After one year from isotope administration, the isotopes will be equally distributed in all body compartments and any change in the isotope abundance with the normal occurring body iron can be detected. From this point onwards, the investigators can observe the iron turnover and calculate iron absorption and losses per unit of time. At 4 different visits blood samples will be taken from each participant.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Females and males aged 18-45 y
BMI: 18 to 25 kg/m2
Body weight <70 kg for females, <85 kg for males
Plasma ferritin >25 µg/L
Disqualifiers
Hb <12 g/dL (females), Hb <13 g/dL (males), corrected for altitude using the 2024 WHO guidance values for hemoglobin adjustments
Inflammation (CRP > 5 mg/L)1
Plasma ferritin >150 µg/L for females and >200 µg/L for males
Chronic disease known to affect iron metabolism
Trial design
Single group
Treatments tested in this trial
Stable Isotopes
Dietary supplement15 mg of stable iron isotopes in the form of ferrous sulphate 57FeSO4 will be orally administered to each participant.
Treatment groups
Trial outcomes
Primary outcomes
57Fe tracer concentration in the circulation
The measurement of the isotopic tracer concentration in the circulation allows to calculate the lon-term iron absorption in the participants, and the rate of change of the tracer allows to calculate the rate of change of body iron.
Secondary outcomes
Hemoglobin mass
Hemoglobin mass will be measured using the CO-rebreathing method. In contrast to hemoglobin concentration, hemoglobin mass is more accurate since it does not depend on blood volume.
Ferritin concentration
Ferritin concentration in serum, expressed as ug/L will be assessed as an indicator of the iron status.
Hepcidin concentration
Hepcidin concentration in serum will be measured as a parameter for the iron status.
Serum transferrin receptor concentration
The serum concentration of the transferrin receptor (TfR) will be measure as a biomarker for iron status.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Diego Moretti
Lead sponsor
Swiss Distance University of Applied Sciences
Sponsor institution
Swiss Federal Institute of Technology
Collaborator
University of Lausanne
Collaborator